The aetiology of most neurodegenerative disorders is multifactorial and consists of an interaction between environmental factors and genetic predisposition. Progression of neurodegenerative diseases in the elderly such as loss of cognitive ability is part of the normal aging process, where methylation is one of the crucial biochemical pathways. The methylation decline brings to a more sensitive oxidative stress; damage to tissue biomolecules, including lipids, proteins and DNA, by free radicals is postulated to contribute importantly to the pathophysiology of oxidative stress.

 

EZ-Brain® is a new patented product, a proprietary combination of SAM-e and SOD, which may help to improve brain functions by exerting a strong antioxidant effect and by restoring the altered DNA methylation. SAM-e (S-Adenosyl-L-Methionine) and SOD (Superoxide Dismutase) can act in synergism for the treatment of dementia through their ability to restore the correct levels of DNA methylation (therefore gene expression) and the correct oxidative balance.

SOD is one of the most important enzymes involved in the scavenging of dangerous Reactive Oxygen Species (ROS) also known as "free radicals".

> Technical Information

Grade: Oral
Description: Transparent capsules, size 0
SAM-e Assay: 200 mg/capsule
SOD Coated Assay: 1750 IU/capsule
Grade: Oral
Description: Transparent capsules, size 00
SAM-e Assay: 400 mg/capsule
SOD Coated Assay: 3500 IU/capsule

Gnosis pre-clinical and clinical trials on EZ-Brain® are available upon request.

SAM-e is the main methyl-donor in eukaryotes and a principal metabolite of homocysteine pathway. It is involved both in methylation of different cellular substrates (DNA in particular) and in maintaining oxidative balance via glutathione synthesis.

 

 

 

 

 

 

 

GNOSIS S.P.A. Sede Legale: Piazza del Carmine, 4 20121 Milano. P. IVA 02484720129 C. F. 10197170151 Cap. Soc. 3.000.000,00 € i.v. Registro delle imprese di Milano N° 10197170151